Skip to main content
  • Speaker presentation
  • Open access
  • Published:

Development of long-acting ARV’s

Research on improved treatment of HIV infection and pre-exposure prophylaxis (PrEP) continues. Poor adherence to treatment is the critical risk factor for virologic failure and resistance development, and long-acting formulations of anti-HIV medications that need only infrequent dosing may facilitate long-term therapeutic responses. However, such formulations and long-term persistence of drug are associated with challenges, such as safety and selective pressure of the drug in case of resistance.

Furthermore, to prevent transmission of HIV, long-acting injectable formulations of ARV agents with infrequent dosing may be advantageous over daily oral drug intake. However, the knowledge on protective drug concentrations and frequency of dosing is poor to date and implementation globally is challenging.

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boffito, M. Development of long-acting ARV’s. BMC Infect Dis 14 (Suppl 2), S11 (2014).

Download citation

  • Published:

  • DOI: